Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
13-Jul-2026 | 270.95 | 271.65 | 266.1 | 269.3 | 17,866 | 30,08,34,156.2 | 5,08,735 |
14-Jul-2026 | 268.95 | 275.3 | 267.7 | 270.95 | 23,188 | 39,25,85,483.55 | 6,00,538 |
15-Jul-2026 | 270.95 | 280 | 270.3 | 275.75 | 26,020 | 47,21,57,684.8 | 6,60,726 |
16-Jul-2026 | 275.8 | 281.4 | 273.65 | 275.35 | 31,432 | 34,91,56,092.9 | 5,81,085 |
17-Jul-2026 | 274.7 | 275 | 263.85 | 267.1 | 35,864 | 37,91,32,876.3 | 6,01,322 |
20-Jul-2026 | 265 | 271.55 | 264.8 | 266.95 | 32,013 | 20,26,97,386.7 | 3,65,428 |
21-Jul-2026 | 268 | 268.1 | 253.05 | 260.3 | 44,436 | 54,57,21,298.65 | 9,42,795 |
22-Jul-2026 | 245 | 249 | 239.65 | 241.1 | 60,981 | 1,04,11,43,614.1 | 16,02,495 |
23-Jul-2026 | 239.9 | 253 | 239.9 | 246.1 | 28,331 | 42,77,27,039.6 | 6,29,930 |
24-Jul-2026 | 244.9 | 248.6 | 242.4 | 246.3 | 21,255 | 19,81,02,154.9 | 3,11,470 |
27-Jul-2026 | 248 | 265.5 | 247.75 | 263.4 | 37,556 | 62,17,92,157.4 | 9,64,809 |
28-Jul-2026 | 263.7 | 265.4 | 254.15 | 256.65 | 20,863 | 24,25,65,466.9 | 4,44,847 |
29-Jul-2026 | 258.2 | 264.15 | 256.85 | 259.45 | 13,788 | 18,39,58,027.45 | 3,13,408 |
30-Jul-2026 | 258.45 | 263.7 | 257.95 | 258.6 | 21,001 | 17,27,89,948.15 | 3,63,348 |
31-Jul-2026 | 260.3 | 262.4 | 252.05 | 258.35 | 20,871 | 18,08,91,352.2 | 3,57,467 |
03-Aug-2026 | 259 | 264 | 258.85 | 262.25 | 18,207 | 17,14,70,970 | 3,55,415 |
04-Aug-2026 | 262.3 | 270.25 | 260.8 | 269.1 | 22,468 | 35,10,85,726.85 | 5,87,046 |
05-Aug-2026 | 271 | 271.8 | 265 | 270.65 | 18,179 | 23,62,20,613.35 | 3,89,318 |
06-Aug-2026 | 270.65 | 276.45 | 267.6 | 268.9 | 23,134 | 33,95,39,818.4 | 6,15,839 |
07-Aug-2026 | 267.25 | 275.4 | 267.25 | 273.85 | 21,029 | 27,55,72,946.4 | 4,84,577 |
In June, Relonchem also secured approval for oxybutynin hydrochloride oral solution, used in managing symptoms of an overactive bladder.
The inspection by the USFDA had taken place between April 16 and 24. After the visit, the company disclosed one observation under Form 483.
The block deal has been launched at a floor price of ₹249.95 per share, signaling a strategic partial exit by the investor.
Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
